GT200000086A - Polimorfos de un citrato de azobiciclo [2.2.2]oct-3-ilamina cristalino y sus composiciones farmaceuticas. - Google Patents

Polimorfos de un citrato de azobiciclo [2.2.2]oct-3-ilamina cristalino y sus composiciones farmaceuticas.

Info

Publication number
GT200000086A
GT200000086A GT200000086A GT200000086A GT200000086A GT 200000086 A GT200000086 A GT 200000086A GT 200000086 A GT200000086 A GT 200000086A GT 200000086 A GT200000086 A GT 200000086A GT 200000086 A GT200000086 A GT 200000086A
Authority
GT
Guatemala
Prior art keywords
polymorphes
citrate
azobiciclo
illamine
oct
Prior art date
Application number
GT200000086A
Other languages
English (en)
Inventor
Stephen Sargent Masset
George Joseph Quallich
Peter Robert Rose
Lewin Theuphilus Wint
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200000086A publication Critical patent/GT200000086A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA INVENCION SE REFIERE AL COMPUESTO DE FORMULA I, AL CITRATO MONOHIDRATO Y A SUS DOS POLIMORFOS A Y B, DADO QUE AMBOS POSEEN PROPIEDADES VALIOSAS, POR EJEMPLO LA ESTABILIDAD HIGROSCOPICA LO CUAL FAVORECE EL ENCAPSULAMIENTO; LA COMPOSICION FARMACEUTICA QUE CONTIENE AL MENOS UNO DE ESTOS POLIMORFOS TIENE UNA ESTABILIDAD VENTAJOSA PARA PACIENTES QUE RECIBEN QUIMIOTERAPIA. LA ADMINISTRACION DE ESTA COMPOSICION FARMACEUTICA ES CONVENCIONALMENTE ORAL, MEDIANTE PREFERIBLEMENTE COMPRIMIDOS O CAPSULAS, E INTRAVENOSA. SE DESCRIBE TAMBIEN UN PROCEDIMIENTO DE OBTENCION DE LAS FORMAS A Y B. LA SAL CITRATO ES UN ANTAGONISTA DEL RECEPTOR NK1 ACTIVO DEL SISTEMA NERVIOSO CENTRAL Y ESTA INVENCION SE REFIERE A PROCEDIMIENTOS DE TRATAMIENTO DE AFECCIONES CAUSADAS O FAVORECIDAS POR UNA DISMINUCION DE LA NEUROTRANSMISION MEDIADA POR LA SUSTANCIA P. ESTA INVENCION SE REFIERE TAMBIEN A UN ANTAGONISTA DE LA SUSTANCIA P, EN EL QUE SE EVALUA LA EFICACIA ANTIEMETICA AGUDA Y RETARDADA EN UN MAMIFERO, INCLUYENDO HUMANOS, QUE RECIBE QUIMIOTERAPIA.
GT200000086A 1999-06-01 2000-05-30 Polimorfos de un citrato de azobiciclo [2.2.2]oct-3-ilamina cristalino y sus composiciones farmaceuticas. GT200000086A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13699599P 1999-06-01 1999-06-01

Publications (1)

Publication Number Publication Date
GT200000086A true GT200000086A (es) 2001-11-21

Family

ID=22475353

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200000086A GT200000086A (es) 1999-06-01 2000-05-30 Polimorfos de un citrato de azobiciclo [2.2.2]oct-3-ilamina cristalino y sus composiciones farmaceuticas.

Country Status (38)

Country Link
US (1) US6387925B1 (es)
EP (1) EP1181289A1 (es)
JP (1) JP2003501353A (es)
KR (1) KR20020005055A (es)
CN (1) CN1353712A (es)
AP (1) AP2001002350A0 (es)
AR (1) AR029753A1 (es)
AU (1) AU767331B2 (es)
BG (1) BG106139A (es)
BR (1) BR0011125A (es)
CA (1) CA2372236A1 (es)
CO (1) CO5170468A1 (es)
CR (1) CR6513A (es)
CZ (1) CZ20014270A3 (es)
DZ (1) DZ3051A1 (es)
EA (1) EA004206B1 (es)
EE (1) EE200100655A (es)
GT (1) GT200000086A (es)
HK (1) HK1046407A1 (es)
HN (1) HN2000000076A (es)
HR (1) HRP20010884A2 (es)
HU (1) HUP0201798A3 (es)
IL (1) IL145952A0 (es)
IS (1) IS6129A (es)
MX (1) MXPA01012328A (es)
NO (1) NO20015845L (es)
NZ (1) NZ514762A (es)
OA (1) OA11955A (es)
PA (1) PA8496001A1 (es)
PE (1) PE20010155A1 (es)
PL (1) PL352715A1 (es)
SK (1) SK17342001A3 (es)
SV (1) SV2002000092A (es)
TN (1) TNSN00119A1 (es)
TR (1) TR200103472T2 (es)
UY (1) UY26177A1 (es)
WO (1) WO2000073303A1 (es)
ZA (1) ZA200109839B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503859A (ja) * 2002-10-04 2006-02-02 メルク シャープ エンド ドーム リミテッド 受容体拮抗薬としてのアザ二環式スピロエーテル誘導体
PT1638937E (pt) * 2003-06-18 2009-01-27 Teva Pharma Forma xiv cristalina de fluvastatina sódica, processos para a sua preparação, composições que a contêm e métodos de utilização
US7371906B2 (en) 2004-08-24 2008-05-13 Eastman Kodak Company Process for photo-oxidative stability improvements
US9446029B2 (en) 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
CN110577522B (zh) * 2018-06-07 2022-12-27 东莞市东阳光动物保健药品有限公司 马罗匹坦柠檬酸盐新晶型及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
RU2103269C1 (ru) * 1991-05-31 1998-01-27 Пфайзер Инк. Производные хинуклидина или их фармацевтически приемлемые соли и фармацевтическая композиция
KR950704311A (ko) * 1992-11-12 1995-11-17 알렌 제이. 스피겔 물질 p 길항체로서의 퀴누클리딘 유도체(quinuclidine derivative as substance p antagonist)
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions

Also Published As

Publication number Publication date
NZ514762A (en) 2002-12-20
CN1353712A (zh) 2002-06-12
AU767331B2 (en) 2003-11-06
CR6513A (es) 2003-11-25
TR200103472T2 (tr) 2002-05-21
CA2372236A1 (en) 2000-12-07
NO20015845L (no) 2002-01-30
CO5170468A1 (es) 2002-06-27
IS6129A (is) 2001-10-26
JP2003501353A (ja) 2003-01-14
EA004206B1 (ru) 2004-02-26
PE20010155A1 (es) 2001-02-08
SV2002000092A (es) 2002-02-05
KR20020005055A (ko) 2002-01-16
HUP0201798A3 (en) 2002-10-28
AR029753A1 (es) 2003-07-16
IL145952A0 (en) 2002-07-25
DZ3051A1 (fr) 2004-03-27
TNSN00119A1 (fr) 2005-11-10
SK17342001A3 (sk) 2002-10-08
BR0011125A (pt) 2002-02-19
MXPA01012328A (es) 2002-07-30
PA8496001A1 (es) 2002-07-30
AP2001002350A0 (en) 2001-12-31
OA11955A (en) 2006-04-13
WO2000073303A1 (en) 2000-12-07
US6387925B1 (en) 2002-05-14
EA200100982A1 (ru) 2002-06-27
EE200100655A (et) 2003-02-17
HUP0201798A2 (en) 2002-09-28
BG106139A (bg) 2002-05-31
AU4424600A (en) 2000-12-18
PL352715A1 (en) 2003-09-08
EP1181289A1 (en) 2002-02-27
HK1046407A1 (zh) 2003-01-10
HRP20010884A2 (en) 2003-04-30
HN2000000076A (es) 2001-02-02
ZA200109839B (en) 2003-01-29
UY26177A1 (es) 2000-12-29
CZ20014270A3 (cs) 2002-08-14
NO20015845D0 (no) 2001-11-30

Similar Documents

Publication Publication Date Title
AR058085A1 (es) Sal de dihidrogeno fosfato de un antagonista del receptor de prostaglandina d2. composiciones farmaceuticas.
UY28496A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
EA200600190A1 (ru) Производные пиримидин-2,4-диона в качестве антагонистов рецептора гонадотропин-высвобождающего гормона
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
MX2009004475A (es) Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
NZ504986A (en) Erythromycin and azalide derivatives and pharmaceutical compositions thereof, useful as antibacterial agents and antoprotozoa agents
RU95106649A (ru) Производные бензимидазола в качестве непептидильных антагонистов рецепторов тахикинина, способ получения, фармацевтическая композиция
EE05103B1 (et) Famatseutilised kompositsioonid, mis sisaldavad asetidiini derivaate, asetidiini derivaadid ja nende valmistamise meetodid
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
ATE412647T1 (de) Substituierte n-arylpyrrolidine als selektive modulatoren des androgenrezeptors
MA30221B1 (fr) Aryldihydro-isoquinoléinones substituées par un azacyclyle, procédé pour leur préparation et leur utilisation en tant que médicaments
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
HK1076605A1 (en) Formulations
EA200500985A1 (ru) Твердая лекарственная форма для перорального применения
EA200870448A1 (ru) Тризамещенные 1,2,4-триазолы
MA31706B1 (fr) Formulations galéniques de composés organiques
IL147852A0 (en) Chemokine receptor antagonists and pharmaceutical compositions containing the same
BG104640A (en) Novel erythromycin derivatives
ATE321047T1 (de) Tricyclische diazepine als tocolytische oxytocin rezeptor antagonisten
EA200100416A1 (ru) 13-членные азалиды и их применение в качестве антибиотических агентов
BR0311189A (pt) Composições farmacêuticas contendo polimorfo a de flibanserin
MA32275B1 (fr) Preparations orales et injectables de composes de tetracycline
EA200500899A1 (ru) Антагонисты аденозиндифосфатного рецептора тромбоцитов
EA200500882A1 (ru) N-арилсульфонил-3-аминоалкоксииндолы
GT200000086A (es) Polimorfos de un citrato de azobiciclo [2.2.2]oct-3-ilamina cristalino y sus composiciones farmaceuticas.